Senseonics Holdings, Inc. (SENS)
Summary
SENS Chart
People also search for
Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.
Senseonics Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Madelyn D. Purcell Pfizer Inc | 2,171 | $22,726.03 | $17,216.03 | -$5,510 | -24.25% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 605 | $3,697.38 | $4,761.35 | $1,063.97 | 28.78% |
| NA Nizar Araji National Bank Of Canada /FI/ | 910 | $13,238 | $6,392.75 | -$6,845.25 | -51.71% |
| MM Mike Masters Masters Capital Management LLC | 700,000 | $4.18M | $5.47M | $1.29M | 30.76% |
| OZI Omar Z. Idilby GMT CAPITAL Corp. | 36,468 | $201,303.36 | $284,632.74 | $83,329.38 | 41.39% |
Senseonics Holdings, Inc. (SENS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Senseonics Holdings, Inc. ever had a stock split?
Senseonics Holdings, Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Timothy T. Goodnow CEO | AMEX Exchange | 81727U303 CUSIP |
| US Country | 130 Employees | - Last Dividend | 20 Oct 2025 Last Split | 17 Mar 2016 IPO Date |
Overview
Senseonics Holdings, Inc. is a medical technology entity dedicated to advancing diabetes care through its innovative continuous glucose monitoring (CGM) solutions. Founded in 1996, with its headquarters set in Germantown, Maryland, Senseonics has been at the forefront of offering advanced CGM systems, tailored for individuals living with diabetes across the United States, Europe, the Middle East, and Africa. The company's primary commitment is to enhance the quality of diabetes management for its users, allowing for real-time and accurate glucose level monitoring, fundamentally changing how people with diabetes manage their condition. Senseonics not only develops and commercializes these CGM systems but also ensures their accessibility to healthcare providers and patients via a robust network of distributors and strategic fulfillment partners. Additionally, the company values collaborative efforts for innovation, as manifested in its partnership with the University Hospitals Accountable Care Organization, aiming to elevate care delivery and outcomes for those managing diabetes.
Products and Services
Eversense
As the initial offering in Senseonics' product line, the Eversense CGM system represents a breakthrough in diabetes management technology. This system is renowned for incorporating an under-the-skin sensor that continuously tracks glucose levels, thus providing real-time, accurate readings. Paired with a removable and rechargeable smart transmitter, Eversense amplifies the convenience and efficiency of monitoring glucose levels, offering a seamless diabetes management experience.
Eversense XL
Building upon the foundation laid by the original Eversense system, the Eversense XL extends the capabilities of continuous glucose monitoring with an enhanced duration of its under-the-skin sensor. Designed for long-term diabetes management, the Eversense XL aims to provide an even more convenient and less intrusive experience for users, reducing the frequency of sensor replacements and thereby improving the overall quality of life for individuals managing their glucose levels.
Eversense E3
The latest innovation in Senseonics' portfolio, the Eversense E3 CGM system, propels glucose monitoring to new heights with a sensor capable of providing accurate glucose measurements for up to six months. This extended duration underscores Senseonics' commitment to advancing diabetes care by minimizing the intrusion and maintenance associated with diabetes management. The Eversense E3 system combines the enduring accuracy of its sensor technology with a user-friendly app and a smart transmitter, ensuring that users have access to real-time glucose data at their fingertips, empowering them to make informed decisions about their diabetes management.
